Regulus Therapeutics | RGLS - Operating Expenses


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Regulus Therapeutics

Regulus Therapeutics reported $7.37M in Operating Expenses for its fiscal quarter ending in March of 2023.


Operating Expenses Change
Alnylam Pharmaceuticals ALNY:US USD 469.1M 54.55M
AstraZeneca AZN:LN USD 8.33B 1.78B
Biogen BIIB:US USD 1.96B 111.2M
Celldex Therapeutics CLDX:US USD 33.44M 3.94M
Gilead Sciences GILD:US USD 4.65B 475M
GlaxoSmithKline GSK:LN GBP 4.87B 640M
Immunic Inc. VTL:US USD 27.25M 30.08M
Incyte Corp INCY:US USD 783.9M 72.7M
Intercept Pharmaceuticals ICPT:US USD 99.59M 4.35M
Intrexon XON:US USD 25.33M 1.77M
Ionis Pharmaceuticals IONS:US USD 244.67M 115.24M
Lexicon Pharmaceuticals LXRX:US USD 31.17M 860K
Ligand Pharmaceuticals LGND:US USD 29.77M 14.9M
Merck & Co MRK:US USD 10.76B 371M
Regulus Therapeutics RGLS:US USD 7.37M 437K
Sangamo BioSciences SGMO:US USD 139.92M 57.3M
Spectrum Pharmaceuticals SPPI:US USD 20.48M 1.27M
Takeda 4502:JP JPY 867.59B 81.97B